PwC Pharmaceutical Drug Pricing and Reporting Issues A Brief Overview of Government Drug Price Reporting Requirements July 28, 2005 National Parma Audioconference.

Slides:



Advertisements
Similar presentations
Issues and Compliance Strategies Related to Government Pricing Joseph W. Metro.
Advertisements

Overview of Drug Purchasing & Pricing
INTEGRITY ● ACCESS ● VALUE 1 The 340B Drug Pricing Program: The Basics Paul Shank Health & Human Services Consultant, Health Resources and Services Administration.
Chapter 6 Federal Regulation of Pharmacy Practice.
Optimizing The 340B Program Promoting Integrity, Access, & Value To deliver clinically and cost-effective pharmacy services This educational product created.
14 th Annual 340B Coalition Conference On Improving Access to Pharmaceutical Care and Ensuring Compliance with Federal and State Laws The Credit and Re-bill.
Optimizing The 340B Program Promoting Integrity, Access, & Value To deliver clinically and cost-effective pharmacy services This educational product created.
Britten Pund, Senior Manager, Health Care Access Emily McCloskey, Manager, Policy and Legislative Affairs The Ryan White Program and 340B Pharmacies.
Health Center Revenue and Reimbursement Management
The Health Care Industry Part 2 - Medical Insurance Karen F. Nichols, MSA School of Allied Health Professions University of Nebraska Medical Center.
555_l21© Allen C. Goodman, 1999 Equity, then Social Insurance … © Allen C. Goodman, 1999.
Alice Valder Curran, Partner Ali Tore, Co-founder & Sr. Director of Product Management Deficit Reduction Act: What You Can and Should Do Now IIR’s 11 th.
Omnibus Budget Reconciliation Act (OBRA-90) Goal To save money.
Meeting the Medication Needs of Iowans: the IowaCare Pilot Pharmaceutical Program and UIHC Medication Assistance Center Lisa Mascardo, PharmD Assistant.
LA Medicaid HEALTHCARE FINANCIAL MANAGEMENT ASSOCIATION PRESENTATION January 30, 2009.
PBM Transactions Medicaid DRA Rule –Proposed Rule AMP includes “Discounts, rebates or other price concessions to PBMs associated with sales for drugs provided.
Affordable Care Act (ACA) The Affordable Care Act
Working Together To Improve Access To Care Presentation to Center for Business Intelligence Patient Assistance Programs Conference March 11, 2003 Alexandria,
340B Drug Discount Program 2013 May 16, 2013 May 16,
The Basics Understanding Health Insurance Terms Jennifer Flory, HIA, CPIW, CGBA.
# Operating Under the New Compliance Environment: Considerations for the Pharmaceutical Industry The Impact of the new Medicare Prescription Drug benefit.
Understanding Discounts Under Federal Law: State Program Opportunities by B ill von Oehsen Principal Powers Pyles Sutter & Verville, PC Senior Fiscal Analysts.
340B: An Overview.
Copyright ©2009 by Pearson Education, Inc. Upper Saddle River, New Jersey All rights reserved. The Pharmacy Technician: Foundations and Practices.
The 340B Program: An Overview NGA/NCSL Web-assisted Audioconference August 5, 2005 Diane P. Goyette, RPh, JD U.S. Department of Health and Human Services.
Government Price Reporting Obligations “A Compliance Discussion”
The Insurance Contract Section Understanding Business and Personal Law The Insurance Contract Section 35.1 Insurance Protection What Is Insurance?
© 2010 Principles of Healthcare Reimbursement Third Edition Chapter 4 Government-Sponsored Healthcare Programs.
State Opportunities under the 340B Drug Discount Program by Bill von Oehsen Counsel Public Hospital Pharmacy Coalition Phone:
National Pharma Audioconference: Pharmaceutical Drug Pricing and Reporting Issues July 28, 2005 Government Price Reporting: Common Problem Areas in a Complex.
Focus on the Drug Payment Methods Landscape Academy of Managed Care Pharmacy April 17, 2009.
Federal Financial Participation (FFP) Overview Office of Family Planning Teen Pregnancy Prevention Program.
PwC *connectedthinking Monitoring and Auditing Around Government Pricing Peter J. Claude PricewaterhouseCoopers LLP November 7, 2005.
Slide 1 Drug Pricing Considerations Medicare Prescription Drug, Improvement, and Modernization Act of 2003 ___________ Copyright 2005 Arnold & Porter July.
© Huron Consulting Services LLC. All rights reserved. Practical Case Study: A Compliance Professional’s Playbook for Conducting a Government Price Reporting.
© Hogan & Hartson LLP. All rights reserved. Alice Valder Curran, Partner Tuesday, October 17, 2006 Private Prices, Public Markets: The Evolution of Price.
Pharmaceutical Pricing Explained
Copyright © 2008 Delmar Learning. All rights reserved. Chapter 15 Medicaid.
1 Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Title III – Combating Waste, Fraud, and Abuse Janet Rehnquist, Esq. Venable LLP.
GOVERNMENT CONTRACTS: FALSE CLAIMS AND COMPLIANCE Robert M. Jenkins III Mayer, Brown & Platt Presentation To The Fifth Annual National Congress on Health.
1 指導教授:周天 所長 報 告 人:碩專班二年級 林俊農 國立高雄第一科技大學 科技法律研究所 案例討論 課程:醫療與法律 案號: 747 F.2d 583, 53 USLW 2237, 7 Soc.Sec.Rep.Serv. 198, Med & Med GD (CCH) P 34,198.
Avalere Health LLC | The intersection of business strategy and public policy The Medicare Modernization Act: The Impact on States and Low-Income Beneficiaries.
Avalere Health LLC | The intersection of business strategy and public policy Overview of Coverage of Drugs Under the Medicaid Medical Benefit June 4, 2008.
Timothy J. Nugent PricewaterhouseCoopers LLP November 7, 2005
Avalere Health LLC | The intersection of business strategy and public policy Medicare Prescription Drug Payment Presented by Margaret Nowak September 24,
340B PRICING AND PROCUREMENT ELIGIBILITY, ENROLLMENT, AND REQUIREMENTS Virtual Health Center’s eHealthUniversity Dr. Erica C. Watkins, PharmD, RPh August.
1.03 Healthcare Finances Understand healthcare agencies, finances, and trends Healthcare Finances Government Finances Private Finances 2.
Medicare Chapter 12 Elsevier items and derived items © 2010, 2008 by Saunders, an imprint of Elsevier Inc.
Health Resources and Services Administration HIV/AIDS Bureau Policy Clarification Notices 15-03: Clarification Regarding the RWHAP and Program Income and.
Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program The Intersection of Business Strategy and Public Policy The Health Strategies.
Medical Coding & Insurance Unit 8 Seminar. CMS Centers for Medicare and Medicaid Services (CMS) Centers for Medicare and Medicaid Services (CMS) Purpose:
MEDICARE PART D July MEDICARE PART D: OVERVIEW Part D provides prescription drug coverage for Medicare beneficiaries. Prescription drug plans compete.
Managed Care Pharmacy Financials January 15, 2015.
Office of Pharmacy Affairs 340B Drug Pricing Program Bradford R. Lang JD, MPH Public Health Analyst US Dept. of Health and Human Services Health Resources.
340B PROGRAM AND BEST PRICE LAW HIGPA 2003 National Pharmacy Forum February 4, 2003 Presentation By Ted Slafsky Director Public Hospital Pharmacy Coalition.
Medicaid Influence in the Drug Market Dana Costea PhD student, Department of Economics, Lehigh University Franklin Carter Assistant Professor, Marketing.
Interactive Workshop Case Study The Pharma Biotech and Device Colloquium Tuesday June 7, 2005.
Changes to AMP & Best Price: Impact on 340B Pricing February 1, 2008 Long Beach, California 4 th Annual 340B Coalition Winter Conference University of.
Clinical Trial Billing and Patient Remuneration
Clinical Medical Assisting
Health Care Systems and Reimbursement
Health Insurance.
Hemophilia Alliance Fall Meeting 2017
Pharmaceutical Pricing and Contracting: An Overview March 2006
1115 Demonstration Waiver Extension Summary
A Short History of Pricing Related Fraud and Abuse Issues 8th Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Washington,
“Netting” Prices Pharmaceutical Compliance Congress November 15, 2004
LEVERAGING PURCHASED/REFERRED CARE (PRC) RATES
Health Care Systems and Reimbursement
Copyright © 2019, The University of Pittsburgh
Presentation transcript:

PwC Pharmaceutical Drug Pricing and Reporting Issues A Brief Overview of Government Drug Price Reporting Requirements July 28, 2005 National Parma Audioconference

Page 2 The Federal Programs Public Health Service * Federal Supply Schedule Program There are currently four types of government pricing programs Medicaid Drug Rebate Program - Will be covered as part of Medicaid Medicare Program

Page 3 Medicaid Program Overview Medicaid, Title XIX of the Social Security Act, is a jointly-funded, Federal- State entitlement program designed to assist States in the provision of adequate medical care to vulnerable and needy individuals and families.  Program eligibility basis includes certain individuals and families with low incomes, the indigent, the aged, the blind and/or disabled.  Medicaid became law in 1965 and is under the administration of the Center for Medicare and Medicaid Services (“CMS”), formerly Health Care Financing Administration (HCFA).  Within broad national guidelines established by Federal statutes, regulations and policies, States have a wide degree of flexibility to design their program, including:  establish eligibility standards;  determine what benefits and services to cover;  set payment rates.

Page 4 Medicaid Drug Rebate Program Cycle *FMAP, the Federal Medical Assistance Percentages are used in determining the amount of Federal matching in State medical and medical insurance expenditures. Wholesaler State Medicaid Agencies Rx Drugs Shipped Utilization Data Reimbursements State-specific % (FMAP*) of rebate payment Rebate Pricing Data Rebate Invoice Rebate Payment, Adjustment, Dispute AMP/BP Data Manufacturer CMS Pharmacy Medicaid Recipient

Page 5 How do you calculate the Medicaid Rebate? The URA calculation is performed on a quarterly basis for each NDC (9-digit level) of a Medicaid covered drug for pharmaceutical products considered to be Innovator and Non-Innovator products Greater of AMP * 15.1% or (AMP - BP) for Innovator products AMP * 11% for Non-Innovator products Current AMP - (Baseline AMP + CPI-U) (Base Rebate + Additional Rebate) Per Unit Unit Rebate Amount (URA) Page 5

Page 6 Public Health Services Program Overview The Public Health Services Program is the program through which the manufacturer agrees to charge eligible entities a price for covered outpatient drugs that will not exceed the amount determined under a statutory formula.  The relevant law related to the PHS pricing is the Veterans Healthcare Act of  Eligible entities are 340B entities including outpatient disproportionate share hospital (DSH) facilities  340B eligible entities can be located on Health Resources and Services Administration (HRSA) website:

Page 7 PHS Program Cycle New PHS Pricing Manufacturer Wholesaler 340B Eligible Entity Drugs Shipped ($70) PHS Prices PHS Pricing ($70) Submit and Pay Chargeback ($30) Drugs Shipped ($100) Wholesale Price = $100 PHS Price = $70 Chargeback = $30

Page 8 How do you calculate PHS pricing Statutory Formula for prices charged to 340B (Disproportionate Share Hospitals (DSH)) eligible entities :  Based on the availability of data, the PHS price is calculated based on one or two quarters prior AMP less the corresponding Medicaid Rebate Per Unit (“RPU”) calculated for the respective quarter Page 8

Page 9 Federal Supply Schedule Program Overview The Federal Supply Schedule (FSS) is the program through which the federal government purchases various products for its own use, including pharmaceuticals and other healthcare products.  The U.S. Congress has delegated responsibility for administering the FSS to the Veterans Administration (VA).  The relevant law related to the FSS contract is the Veterans Healthcare Act of  The largest purchasers of pharmaceuticals within the federal government are the VA, DoD, Indian Health Service, and Coast Guard.  These entities (a.k.a. The Big Four) purchase over $2 billion in pharmaceuticals each year.  The VA and DoD alone operate over five hundred hospitals, medical centers, and clinics.

Page 10 FSS Program Cycle VA National Acquisition Center Manufacturer Wholesaler VA/DOD Facility Drugs Shipped ($70) PHS Prices PHS Pricing ($70) Submit and Pay Chargeback ($30) Drugs Shipped ($100) Wholesale Price = $100 PHS Price = $70 Chargeback = $30

Page 11 Federal Supply Schedule Pricing Process Pricing on the FSS is determined by taking the lower of the Federal Ceiling Price as calculated under the Veterans Health Care Act and the negotiated price (based on Most Favored Customer) under the terms of the contract. Negotiated under the terms of the contract No minimum discount Customer tracking requirement Calculated according to formulas prescribed by law Minimum discount of 24% MFCFCP Lower of 2 Prices FSS Price Page 11

Page 12 Federal Ceiling Price Process The FCP is a calculated value that is derived through a three step process. Non-FAMP Non-FAMP Adjustment Lower of Two Prices FCP Annual Quarterly Minimum discount of 24% Prior Year FSS + CPI-U Max FSS Page 12

Page 13 Medicare Part B Overview The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 required manufacturers to submit on a quarterly basis to CMS the “Manufacturer’s Average Sale Price” (ASP) based on a statutory formula and guidance provided by CMS  ASP pricing data is submitted quarterly for Medicare Part B reimbursable products  1Q04 was the first quarter ASP pricing was required to be submitted to CMS by April 30, 2004  Beginning January 1, 2005, CMS started using the reported ASP prices to reimburse physicians for Part B drugs not paid on a cost or prospective payment basis  Because the reported ASP pricing is used for reimbursement purposes, there is no re-filing mechanism available to the manufacturer (unlike the re-filing mechanism available for Medicaid Rebate Reporting)  The manufacturer’s CEO, CFO or an individual who has delegated authority to sign for, and who reports directly to the CEO or CFO needs to certify to the accuracy of the calculations

Page 14 Medicare ASP Pricing Cycle Manufacturer CMS Physicians Reimburse based on ASP pricing Submitted by Manufacturer ASP Pricing Submitted on a Quarterly Basis

Page 15 Data Integrity Manufacturers should understand the data and process flow of all information being interfaced into the government price reporting system. This should include discussion with users and IT personnel to map out the following:  All data sources used  All transactions included / excluded during the interface, as well as, within the Government Pricing system  Understanding of system edit checks and reports generated by the interface system, as well as, the Government Pricing system  What is being done with each of these reports and errors discovered during the edit checks Manufacturers should develop and maintain well documented policies and procedures around all of the data interfaces, which take into consideration the use of the data when performing the Government Price calculations

Page 16 Data Integrity, cont’d Product Data – Produce type, NDC, etc Indirect Sales Transactions – Chargeback data Customer Data Records – Contract eligibility, class of trade, etc Order Entry System - Direct Sales, credits and returns Best Price Calculation Process AMP Calculation Process State Rebate and Price Submission Process Sales and Discount Programs (Deals) Government Price Reporting Systems VA Price Reporting Medicare ASP Price Reporting PHS Price Reporting Understanding your systems and data interfaces

Page 17 Data Integrity, cont’d The following outlines questions to be considered when reviewing the data interfaces:  What are the data interfaces into the government price reporting system  What formal written policies and procedures exist, when were they developed and have they been reviewed by counsel and management  Has a risk assessment been performed to ensure the policies and procedures that are in place are actually being followed  What controls exist around this data within the interfacing systems, as well as, once the data is gathered and implemented in the government price reporting calculations  What is being done with the data once it is gathered into the government price reporting system  Does proper supervision and training exist  How can information be overridden and who has the ability to perform overrides  How are transactions being valued and what is the effect on the government pricing calculations  When was the system reviewed to evaluate if all relevant customer information and transaction data is being extracted properly  Assess whether appropriate data retention and audit trails exist